Class A · CUSIP 46333X108 · who reports it, how much, and how much it matters to them
15 of the 720 hedge fund managers we track reported shares of Ironwood Pharmaceuticals Inc (Nasdaq: IRWD) on Form 13F for 30 June 2026. Between them they reported USD 174m. The largest position belongs to Armistice Capital, at USD 59m. The manager with the most riding on it is Sarissa Capital Management, where it is 21.7% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Armistice Capital1 fund on PPLI.com | USD 59m | 0.7% |
| 2 | Sarissa Capital Management6 funds on PPLI.com | USD 39m | 21.7% |
| 3 | Renaissance Technologies13 funds on PPLI.com | USD 34m | 0.0% |
| 4 | Two Sigma Investments35 funds on PPLI.com | USD 19m | 0.0% |
| 5 | Marshall Wace LLP84 funds on PPLI.com | USD 18m | 0.0% |
| 6 | Citadel Advisors32 funds on PPLI.com | USD 2.1m | 0.0% |
| 7 | CM Management1 fund on PPLI.com | USD 1.5m | 0.9% |
| 8 | D. E. Shaw & Co.15 funds on PPLI.com | USD 517,000 | 0.0% |
| 9 | Cercano Management5 funds on PPLI.com | USD 427,000 | 0.1% |
| 10 | Engineers Gate Manager1 fund on PPLI.com | USD 413,000 | 0.0% |
| 11 | Squarepoint Ops7 funds on PPLI.com | USD 282,000 | 0.0% |
| 12 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 120,000 | 0.0% |
| 13 | Prelude Capital Management9 funds on PPLI.com | USD 77,464 | 0.0% |
| 14 | The Quarry1 fund on PPLI.com | USD 1,149 | 0.0% |
| 15 | Walleye Capital8 funds on PPLI.com | USD 4 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Sarissa Capital Management | USD 39m | 21.7% |
| 2 | CM Management | USD 1.5m | 0.9% |
| 3 | Armistice Capital | USD 59m | 0.7% |
| 4 | Cercano Management | USD 427,000 | 0.1% |
| 5 | Renaissance Technologies | USD 34m | 0.0% |
| 6 | Two Sigma Investments | USD 19m | 0.0% |
| 7 | Marshall Wace LLP | USD 18m | 0.0% |
| 8 | Prelude Capital Management | USD 77,464 | 0.0% |
| 9 | Engineers Gate Manager | USD 413,000 | 0.0% |
| 10 | Citadel Advisors | USD 2.1m | 0.0% |
Ironwood Pharmaceuticals Inc trades under the symbol IRWD on the Nasdaq. Its CUSIP, the code used on Form 13F, is 46333X108.
15 of the 720 hedge fund managers PPLI.com tracks reported Ironwood Pharmaceuticals Inc shares on Form 13F for 30 June 2026. The largest reported positions were held by Armistice Capital (USD 59m), Sarissa Capital Management (USD 39m), Renaissance Technologies (USD 34m), Two Sigma Investments (USD 19m) and Marshall Wace LLP (USD 18m).
15 managers in our coverage reported it, and between them they run 248 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Sarissa Capital Management, where the position was 21.7% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Ironwood Pharmaceuticals Inc or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.